Skip to main content

Payers' Guide

FDA Approvals, Payers' Guide

Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

Competition Heats Up in Rheumatoid Arthritis and Other Autoimmune Conditions

Gary Branning, MBA

FDA Approvals, Payers' Guide

Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

The Sixth Annual Payers’ Guide to New FDA Approvals

Introduction, Payers' Guide

New FDA Drug Approvals Hit an 18-Year High in 2014

Gary M. Owens, MD

Payers' Guide, FDA Approvals

FDA Approvals of Brand-Name Prescription Drugs in 2014

Payers' Guide, FDA Approvals

Afrezza (Insulin Human) Inhalation Powder Approved for the Treatment of Patients with Type 1 or Type 2 Diabetes

Payers' Guide, FDA Approvals

Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Lisa A. Raedler, PhD, RPh

Page 11 of 19
Results 101 - 110 of 185